182 related articles for article (PubMed ID: 28944726)
1. Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs.
Yeung K; Suh K; Basu A; Garrison LP; Bansal A; Carlson JJ
J Manag Care Spec Pharm; 2017 Oct; 23(10):1084-1090. PubMed ID: 28944726
[TBL] [Abstract][Full Text] [Related]
2. The Current Status of Outcomes-Based Contracting for Manufacturers and Payers: An AMCP Membership Survey.
Duhig AM; Saha S; Smith S; Kaufman S; Hughes J
J Manag Care Spec Pharm; 2018 May; 24(5):410-415. PubMed ID: 29337604
[TBL] [Abstract][Full Text] [Related]
3. Does a One-Size-Fits-All Cost-Sharing Approach Incentivize Appropriate Medication Use? A Roundtable on the Fairness and Ethics Associated with Variable Cost Sharing.
Graff JS; Shih C; Barker T; Dieguez G; Larson C; Sherman H; Dubois RW
J Manag Care Spec Pharm; 2017 Jun; 23(6):621-627. PubMed ID: 28530519
[TBL] [Abstract][Full Text] [Related]
4. Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals.
Greene L; Singh RM; Carden MJ; Pardo CO; Lichtenstein GR
J Manag Care Spec Pharm; 2019 Aug; 25(8):904-912. PubMed ID: 31007119
[TBL] [Abstract][Full Text] [Related]
5. AMCP Partnership Forum: What's Next for Specialty Medication Benefit Design and Reimbursement.
J Manag Care Spec Pharm; 2020 Oct; 26(10):1206-1213. PubMed ID: 32780612
[TBL] [Abstract][Full Text] [Related]
6. Meeting the affordability challenges posed by orphan drugs: a survey of payers, providers, and employers.
Lopata E; Terrone C; Gopalan A; Ladikos N; Richardson T
J Manag Care Spec Pharm; 2021 Jun; 27(6):706-713. PubMed ID: 33586514
[No Abstract] [Full Text] [Related]
7. AMCP Partnership Forum: Designing Benefits and Payment Models for Innovative High-Investment Medications.
J Manag Care Spec Pharm; 2019 Feb; 25(2):156-162. PubMed ID: 30698091
[TBL] [Abstract][Full Text] [Related]
8. AMCP Partnership Forum: FDAMA Section 114-Improving the Exchange of Health Care Economic Data.
J Manag Care Spec Pharm; 2016 Jul; 22(7):826-31. PubMed ID: 27333323
[TBL] [Abstract][Full Text] [Related]
9. Performance-Based Risk-Sharing Arrangements: U.S. Payer Experience.
Goble JA; Ung B; van Boemmel-Wegmann S; Navarro RP; Parece A
J Manag Care Spec Pharm; 2017 Oct; 23(10):1042-1052. PubMed ID: 28944728
[TBL] [Abstract][Full Text] [Related]
10. Validating a Budget Impact Model Using Payer Insight and Claims Data: A Framework and Case Study.
Hung A; Slejko JF; Lugo A; Shaya F; Haines ST; Mullins CD
J Manag Care Spec Pharm; 2019 Aug; 25(8):913-921. PubMed ID: 31347981
[TBL] [Abstract][Full Text] [Related]
11. Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers.
Nichol MB; Knight TK; Epstein J; Honda DH; Tretiak R
J Manag Care Pharm; 2007 May; 13(4):360-71. PubMed ID: 17506602
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Formulary Restrictions on Patient and Payer Outcomes: A Systematic Literature Review.
Park Y; Raza S; George A; Agrawal R; Ko J
J Manag Care Spec Pharm; 2017 Aug; 23(8):893-901. PubMed ID: 28737993
[TBL] [Abstract][Full Text] [Related]
13. Low-Cost Generic Program Use by Medicare Beneficiaries: Implications for Medication Exposure Misclassification in Administrative Claims Data.
Pauly NJ; Talbert JC; Brown J
J Manag Care Spec Pharm; 2016 Jun; 22(6):741-51. PubMed ID: 27231801
[TBL] [Abstract][Full Text] [Related]
14. Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based Pricing.
Yeung K; Li M; Carlson JJ
J Manag Care Spec Pharm; 2017 Oct; 23(10):1010-1015. PubMed ID: 28944729
[TBL] [Abstract][Full Text] [Related]
15. Racial disparities in medication use: imperatives for managed care pharmacy.
Kogut SJ
J Manag Care Spec Pharm; 2020 Nov; 26(11):1468-1474. PubMed ID: 33119445
[TBL] [Abstract][Full Text] [Related]
16. Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
Hurwitz JT; Brown M; Graff JS; Peters L; Malone DC
J Manag Care Spec Pharm; 2017 Jun; 23(6):613-620. PubMed ID: 28530524
[TBL] [Abstract][Full Text] [Related]
17. AMCP Partnership Forum: Enabling the Exchange of Clinical and Economic Information Pre-FDA Approval.
J Manag Care Spec Pharm; 2017 Jan; 23(1):105-112. PubMed ID: 28025919
[TBL] [Abstract][Full Text] [Related]
18. Advancing a managed care pharmacy research agenda: Generating real-world evidence to support US Food and Drug Administration Accelerated Approvals and improving benefit design to address health inequities.
Brixner D; Couto J; Worley K; Small A; Panchal R; Dharbhamalla V; Eichenbrenner P
J Manag Care Spec Pharm; 2022 Aug; 28(8):911-917. PubMed ID: 35722828
[TBL] [Abstract][Full Text] [Related]
19. Adherence, Persistence, and Expenditures for High-Cost Anti-Inflammatory Drugs in Rheumatoid Arthritis: An Exploratory Study.
Khilfeh I; Guyette E; Watkins J; Danielson D; Gross D; Yeung K
J Manag Care Spec Pharm; 2019 Apr; 25(4):461-467. PubMed ID: 30917076
[TBL] [Abstract][Full Text] [Related]
20. Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management "Tune-Up" Clinic.
Hirsch JD; Bounthavong M; Arjmand A; Ha DR; Cadiz CL; Zimmerman A; Ourth H; Morreale AP; Edelman SV; Morello CM
J Manag Care Spec Pharm; 2017 Mar; 23(3):318-326. PubMed ID: 28230459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]